SCHEMBL7182380

SCHEMBL7182380

Oc1cc(Cl)ccc1Oc1ccc(F)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.58
LMNA P02545 2/20 0.58
MAPT P10636 2/20 0.58
HPGD P15428 2/20 0.58
NR1I2 O75469 1/20 0.58
PGR P06401 1/20 0.58
HSP90AA1 P07900 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
HSPA5 P11021 1/20 0.58
CBR1 P16152 1/20 0.58
TBXA2R P21731 1/20 0.58
SLC6A2 P23975 1/20 0.58
AGTR1 P30556 1/20 0.58
SLC6A3 Q01959 1/20 0.58
HTR2C P28335 3/20 0.48
HTR2B P41595 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HTR2A P28223 2/20 0.48
SLC6A4 P31645 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Soneclosan SCHEMBL29359126 0.89 TTR (0.66) TTRLMNAMAPTHPGDNR1I2
Soneclosan SCHEMBL465591 0.89 TTR (0.66) TTRLMNAMAPTHPGDNR1I2
SCHEMBL5989716 0.86 HTR2C (0.48) LMNAMAPTHPGDHTR2CHTR2B
SCHEMBL13778174 0.82 TTR (0.58) TTRLMNAMAPTHPGDNR1I2
SCHEMBL14157301 0.82 HPGD (0.58) TTRLMNAMAPTHPGDNR1I2
SCHEMBL24252977 0.82 HTR2C (0.48) LMNAMAPTHPGDHTR2CHTR2B
SCHEMBL7176805 0.82 TTR (0.58) TTRLMNAMAPTHPGDNR1I2
SCHEMBL4416209 0.82 TTR (0.58) TTRLMNAMAPTHPGDNR1I2
SCHEMBL30451605 0.82 HTR2C (0.48) LMNAMAPTHPGDHTR2CHTR2B
SCHEMBL10940178 0.81 CYP1A2 (0.62) TTRLMNAMAPTHPGDNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349453-A2 BIOCIDE COMPOSITIONS AND METHODS AND SYSTEMS EMPLOYING SAME THE PROCTER & GAMBLE COMPANY (US) 2003-10-08 EP disclosed
US-20020068014-A1 Antibacterial agents and compositions, methods and systems employing same PROCTER & GAMBLE COMPANY, THE 2002-06-06 US disclosed
US-20020014178-A1 Biocide compositions and methods and systems employing same PROCTER & GAMBLE COMPANY, THE 2002-02-07 US disclosed
WO-2002005643-A2 BIOCIDE COMPOSITIONS AND METHODS AND SYSTEMS EMPLOYING SAME THE PROCTER & GAMBLE COMPANY (US) 2002-01-24 WO disclosed
WO-2001060157-A2 ANTIBACTERIAL AGENTS AND COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2001-08-23 WO disclosed
US-4326978-A A HALOGENATED O-HYDROXY- DIPHENYL ETHER, AND MAGNESIUM SILICATE TO INHIBIT DISCOLORATION CIBA-GEIGY CORPORATION (US) 1982-04-27 US disclosed
US-4111844-A 2,4,4'-TRICHLORO-2'-HYDROXY-DIPHENYL ETHER, ANIONIC SURFACTANT, WATER CIBA-GEIGY CORPORATION (US) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068014-A1 Antibacterial agents and compositions, methods and systems employing same SPOUT1, PGLS, TLR6 TTR 2946/4885LMNA 4096/4885MAPT 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.